Humana (HUM) Q2 2025 Earnings Transcript

The market is likely underestimating how much of the near-term upside is now becoming self-reinforcing: better MA retention reduces the severity of adverse selection, which in turn improves pricing confidence and lowers the probability of another destructive benefit reset. That matters because Humana’s biggest swing factor is no longer just membership count, but the quality of the book entering 2026; bounce-back members and improved recapture suggest the company is stabilizing the risk pool rather than merely buying growth. If that dynamic holds through AEP/OEP, the earnings trajectory can improve even without a dramatic step-up in top-line enrollment.

The more important second-order read is that CenterWell Pharmacy is becoming a meaningful internal hedge against MA margin volatility. Direct-to-consumer and specialty access expansion add a mix shift that is less exposed to pure utilization politics than core insurance, and the company’s willingness to pull some investment forward suggests management sees unusually high marginal returns in retention and care-navigation tools. That should help medium-term multiple support, but it also means 2025-2026 EPS is somewhat less clean than the headline guidance implies because execution risk is now spread across more moving pieces.

The biggest unresolved overhang is regulatory: Stars litigation, RADV, and home health reimbursement are all potentially asymmetric, but on different time horizons. Near term, the stock can re-rate if investors believe the 2027 Stars risk is contained and 2026 bid assumptions are de-risked; over 6-12 months, however, any evidence that the richer-benefit gap narrows faster than expected could pressure retention and margin simultaneously. The contrarian view is that the consensus is still treating Humana like a damaged MA insurer when it increasingly behaves like a managed healthcare platform with a growing services/pharmacy earnings engine and more disciplined capital allocation.